Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People with a general health and activity level rated as reasonably functional (a standard cancer performance scale score of 2 or below)
- People of any gender
- For Part A of the trial: People with one of the listed cancer types that was either newly diagnosed or diagnosed no more than 24 months ago, with spread outside the brain (non-CNS metastases). The cancer types included are: triple negative breast cancer, HER2-positive breast cancer, non-small cell lung cancer, small cell lung cancer, melanoma, or other solid tumours not listed here
- For Part B of the trial: People with one of the listed cancer types, including those with a confirmed cancer spread to the lining of the brain or spinal cord (called leptomeningeal carcinomatosis), who are experiencing their first brain-related event and have not yet joined the study
- People who have stored tumour tissue samples available (from either the original tumour or a spread site outside the brain) — this is required to join
- People who are willing to have a lumbar puncture (spinal fluid sample) taken when brain involvement is diagnosed, unless there is a medical reason not to
- People with a life expectancy of more than 3 months
- Women who could become pregnant must have had a negative pregnancy test within 28 days before joining
- Women who could become pregnant must have an effective form of contraception in place
- People who have completed all required screening tests within 28 days before joining
- People who have signed a consent form before any study procedures begin
- (For participants in France only) People who are registered with the French Social Security system
Who may not be able to join:
- Women who are pregnant or currently breastfeeding
- People who have had or currently have a different type of cancer within the past 2 years — with the exception of certain early-stage skin cancers or early cervical changes that have been adequately treated
- People who have a significant medical, psychiatric, or surgical condition that is not currently under control and that, in the lead doctor's opinion, could interfere with completing the study
- (For participants in France only) People who are considered legally vulnerable under French public health law, or who are under a form of legal protection, or who are unable to give their own consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nuria Kotecki, MD, Jules Bordet Institute
Phone: +322541
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Better understanding of the epidemiology of CNS metastases from solid tumours; Better understanding of the epidemiology of CNS metastases from solid tumours; Better understanding of the epidemiology of CNS metastases from solid tumours; Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.; Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.; Better understand the biology of CNS metastases...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.